---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-030631"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2025-10-07T23:59:59+00:00"
generated_at: "2026-05-17T04:31:36.049108+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ImmuCell Q3 sales fall 8% to $5.5M; 9-month sales up 7% to $20M

## Summary
- Preliminary Q3 2025 product sales $5.5M vs $6.0M in Q3 2024, an 8% decrease.
- Nine-month 2025 sales $20.0M, up 7% from $18.7M; trailing twelve-month sales $27.8M, up 16%.
- Drop attributed to end of distributor restocking that boosted H1 2025; guidance warned of H2 softening.
- Re-Tain Investigational Product use started in controlled study with Michigan State; no revenue expected.
- Non-Administrative NADA for Re-Tain submitted Jan. 2025; clearance of contract manufacturer inspection remaining hurdle.

## SEC filing metadata
- accession: 0001437749-25-030631
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2025-10-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000143774925030631/0001437749-25-030631-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000143774925030631/iccc20251007_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-030631
- JSON: https://secwatch.observer/filing/0001437749-25-030631.json
- Plain text: https://secwatch.observer/filing/0001437749-25-030631.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.